Stock Code: 6446 Company Name: PharmaEssentia Corp. Industry: Biotechnology & Medical Care Data for: 2026-02 Monthly Revenue: 1,600,454 (in thousands of NTD), or 1.60 billion Year-over-Year Change: +56.7%
FACT BOX
- Source: PR Times
- Category: 其他
其他
【PharmaEssentia】February 2026 Revenue Reaches 1.60 Billion (YoY +56.7%)
Citation-Grade
Primary-source linked
Schema.org verified
NQ 67 / 100
Published Feb 1, 2026 9:00 AM ・ Updated Jun 15, 2026 12:30 AM ・ 2 min read ・ Source: PR Times
Show contents
⚡ Key Points
- PharmaEssentia, a new drug development company, announced that its revenue for February 2026 reached 1.60 billion, a year-over-year increase of 56.7%.
- This strong performance is primarily attributed to the sales of its new drug for treating polycythemia vera, highlighting its success in the biotechnology and healthcare market.
PharmaEssentia, a new drug development company, announced that its revenue for February 2026 reached 1.60 billion, a year-over-year increase of 56.7%. This strong performance is primarily attributed to the sales of its new drug for treating polycythemia vera, highlighting its success in the biotechnology and healthcare market.
Editorial & Verification Standards
The Washin AI News desk structures and reviews this article under the following standards.
- Start only from primary sources (official PR, disclosures, wire services)
- Numbers and proper nouns machine-checked against the source (number-completeness check)
- Company names and tickers verified via registry (Registry/TWSE/Wikidata)
- No speculation; nothing stated that is not in the source
Editorial log (Published → Collected → AI analysis → Published: transparency timeline)›
- Announced Feb 1, 2026 9:00 AM — Distributor PR Times
- Collected Apr 7, 2026 8:00 AM
- AI structured & analyzed Apr 8, 2026 12:19 AM
- Desk-reviewed & published Feb 1, 2026 9:00 AM
FAQ
What was PharmaEssentia's revenue in February 2026?
PharmaEssentia's revenue in February 2026 reached 1.60 billion NTD.
How much did PharmaEssentia's revenue increase year-over-year in February 2026?
PharmaEssentia's revenue saw a year-over-year increase of 56.7% in February 2026.
What is the stock code for PharmaEssentia Corp.?
The stock code for PharmaEssentia Corp. is 6446.
In which industry does PharmaEssentia Corp. operate?
PharmaEssentia Corp. operates in the Biotechnology & Medical Care industry.
What was the exact monthly revenue figure for PharmaEssentia in February 2026, in thousands of NTD?
The exact monthly revenue figure for PharmaEssentia in February 2026 was 1,600,454 thousand NTD.
Cite this article — HOW TO CITE
Washin AI News Desk“【PharmaEssentia】February 2026 Revenue Reaches 1.60 Billion (YoY +56.7%)”AI News by Washin Village（和心村）, Feb 1, 2026. https://aeo.idaeo.ai/ai/%E8%97%A5%E8%8F%AF%E8%97%A5/en/news/2026-04-07-yao
AI CRAWLER ACTIVITY
as of Aug 17, 2026
AI crawler visits to this article (cumulative)31 bots
Site-wide cumulative
Applebot
bot_visits_summary
2830k
last Aug 17, 2026
GPTBot
bot_visits_summary
2063k
last Aug 17, 2026
Bingbot
bot_visits_summary
758k
last Aug 17, 2026
ClaudeBot
bot_visits_summary
616k
last Aug 17, 2026
Amazonbot
bot_visits_summary
600k
last Aug 17, 2026
Meta AI
bot_visits_summary
478k
last Aug 17, 2026
※ Only measured values from bot_visits_summary / crawler_url_hits are shown. Article-level zero counts are shown as measuring.
Washin AI News（AI News by Washin Village（和心村））
An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.
Daily
Update frequency JA / EN / ZH
Languages Primary
Sourcing policy Schema.org
Structured verification
Update frequency JA / EN / ZH
Languages Primary
Sourcing policy Schema.org
Structured verification
Get your announcement indexed as AI-citable structured news.
Primary-source links, three languages, Schema.org verified.Talk to us about coverage →
Primary-source links, three languages, Schema.org verified.Talk to us about coverage →